Minghui Pharmaceutical (Hangzhou) Ltd

Quick facts

Phase 3 pipeline

• Furmonertinib · Other
• MH004 Ointment · Dermatology
  MH004 is a topical ointment formulation designed to treat dermatological conditions through localized therapeutic action.
• MHB018A injection
  MHB018A injection's mechanism is not publicly available.

Phase 1 pipeline

• MH004 0.1% Ointment
• MH004 0.3% Ointment
• MH004 1.0% Ointment
• MH004 3.0% Ointment
• MHB036C
• MHB039A
• MHB046C

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Minghui Pharmaceutical (Hangzhou) Ltd portfolio CI brief
• Minghui Pharmaceutical (Hangzhou) Ltd pipeline updates RSS